Moyra Lawrence

Moyra Lawrence

Auto-generated profile, based on publicly available information

Moyra Lawrence

Department of Haematology, Cambridge Blood Centre, National Health Service Blood and Transplant, University of Cambridge, Cambridge, United Kingdom

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Trends in Genetics
Verified
Journal Article
Closed access
MLMoyra Lawrence
Moyra Lawrence
SDSylvain Daujat
Sylvain Daujat
RSRobert Schneider
Robert Schneider

10 February 2013 in Nature
Verified
Journal Article
Open access
PDF file
YCYael Costa
Yael Costa
JDJunjun Ding
Junjun Ding
TTThorold W. Theunissen
Thorold W. Theunissen
FFFrancesco Faiola
Francesco Faiola
THTimothy A. Hore
Timothy A. Hore
JWJianlong Wang
Jianlong Wang
The authors show that the pluripotency factor NANOG interacts with TET1 and TET2 methylcytosine hydroxylases, and that the hydroxylation of 5-methylcytosine to 5-hydroxymethylcytosine enhances the efficiency of somatic cell reprogramming in a NANOG-dependent manner. This study provides new insight into the reprogramming mechanism of the pluripotency factor NANOG by showing that two TET family 5-methylcytosine (5mC) hydroxylases, TET1 and TET2, interact with it. TET1 and TET2 facilitate reprogramming in a manner that is dependent on their catalytic activity. This represents the first report of a role for 5mC hydroxylases in the establishment of naive pluripotency. Molecular control of the pluripotent state is thought to reside in a core circuitry of master transcription factors including the homeodomain-containing protein NANOG1,2, which has an essential role in establishing ground state pluripotency during somatic cell reprogramming3,4. Whereas the genomic occupancy of NANOG has been extensively investigated, comparatively little is known about NANOG-associated proteins5 and their contribution to the NANOG-mediated reprogramming process. Using enhanced purification techniques and a stringent computational algorithm, we identify 27 high-confidence protein interaction partners of NANOG in mouse embryonic stem cells. These consist of 19 previously unknown partners of NANOG that have not been reported before, including the ten-eleven translocation (TET) family methylcytosine hydroxylase TET1. We confirm physical association of NANOG with TET1, and demonstrate that TET1, in synergy with NANOG, enhances the efficiency of reprogramming. We also find physical association and reprogramming synergy of TET2 with NANOG, and demonstrate that knockdown of TET2 abolishes the reprogramming synergy of NANOG with a catalytically deficient mutant of TET1. These results indicate that the physical interaction between NANOG and TET1/TET2 proteins facilitates reprogramming in a manner that is dependent on the catalytic activity of TET1/TET2. TET1 and NANOG co-occupy genomic loci of genes associated with both maintenance of pluripotency and lineage commitment in embryonic stem cells, and TET1 binding is reduced upon NANOG depletion. Co-expression of NANOG and TET1 increases 5-hydroxymethylcytosine levels at the top-ranked common target loci Esrrb and Oct4 (also called Pou5f1), resulting in priming of their expression before reprogramming to naive pluripotency. We propose that TET1 is recruited by NANOG to enhance the expression of a subset of key reprogramming target genes. These results provide an insight into the reprogramming mechanism of NANOG and uncover a new role for 5-methylcytosine hydroxylases in the establishment of naive pluripotency.

12 April 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
AEAmanda L. Evans
Amanda L. Evans
ADAmanda Dalby
Amanda Dalby
HFHolly R. Foster
Holly R. Foster
DHDaniel Howard
Daniel Howard
AWAmie K. Waller
Amie K. Waller
CGCedric Ghevaert
Cedric Ghevaert
The production of in vitro–derived platelets has great potential for transfusion medicine. Here, we build on our experience in the forward programming (FoP) of human pluripotent stem cells (hPSCs) to megakaryocytes (MKs) and address several aspects of the complex challenges to bring this technology to the bedside. We first identify clinical-grade hPSC lines that generate MKs efficiently. We design a bespoke media to maximize both production and maturity of MKs and improve platelet output. Crucially, we transition the lentiviral-based FoP of hPSCs to a nonviral inducible system. We also show how small molecules promote a definitive hematopoiesis phenotype during the differentiation process, thereby increasing the quality of the final product. Finally, we generate platelets using a bioreactor designed to reproduce the physical cues that promote platelet production in the bone marrow. We show that these platelets are able to contribute to both thrombus formation in vitro and have a hemostatic effect in thrombocytopenic mice in vivo.

7 April 2022 in Blood
Verified
Journal Article
Open access
PDF file
CBCavan Bennett
Cavan Bennett
MLMoyra Lawrence
Moyra Lawrence
JGJose A. Guerrero
Jose A. Guerrero
SSSimon Stritt
Simon Stritt
AWAmie K. Waller
Amie K. Waller
CGCedric Ghevaert
Cedric Ghevaert
The process of platelet production has so far been understood to be a 2-stage process: megakaryocyte maturation from hematopoietic stem cells followed by proplatelet formation, with each phase regulating the peripheral blood platelet count. Proplatelet formation releases into the bloodstream beads-on-a-string preplatelets, which undergo fission into mature platelets. For the first time, we show that preplatelet maturation is a third, tightly regulated, critical process akin to cytokinesis that regulates platelet count. We show that deficiency in cytokine receptor-like factor 3 (CRLF3) in mice leads to an isolated and sustained 25% to 48% reduction in the platelet count without any effect on other blood cell lineages. We show that Crlf3−/− preplatelets have increased microtubule stability, possibly because of increased microtubule glutamylation via the interaction of CRLF3 with key members of the Hippo pathway. Using a mouse model of JAK2 V617F essential thrombocythemia, we show that a lack of CRLF3 leads to long-term lineage-specific normalization of the platelet count. We thereby postulate that targeting CRLF3 has therapeutic potential for treatment of thrombocythemia.

26 May 2021 in npj Regenerative Medicine
Verified
Journal Article
Open access
PDF file
MLMoyra Lawrence
Moyra Lawrence
AEAmanda Evans
Amanda Evans
TMThomas Moreau
Thomas Moreau
MBMarta Bagnati
Marta Bagnati
MSMatthew Smart
Matthew Smart
CGCedric Ghevaert
Cedric Ghevaert
Quality, traceability and reproducibility are crucial factors in the reliable manufacture of cellular therapeutics, as part of the overall framework of Good Manufacturing Practice (GMP). As more and more cellular therapeutics progress towards the clinic and research protocols are adapted to comply with GMP standards, guidelines for safe and efficient adaptation have become increasingly relevant. In this paper, we describe the process analysis of megakaryocyte manufacture from induced pluripotent stem cells with a view to manufacturing in vitro platelets to European GMP for transfusion. This process analysis has allowed us an overview of the entire manufacturing process, enabling us to pinpoint the cause and severity of critical risks. Risk mitigations were then proposed for each risk, designed to be GMP compliant. These mitigations will be key in advancing this iPS-derived therapy towards the clinic and have broad applicability to other iPS-derived cellular therapeutics, many of which are currently advancing towards GMP-compliance. Taking these factors into account during protocol design could potentially save time and money, expediting the advent of safe, novel therapeutics from stem cells.

17 April 2019 in Emerging Topics in Life Sciences
Verified
Journal Article
Open access
PDF file
MLMoyra Lawrence
Moyra Lawrence
AMAnnett Mueller
Annett Mueller
CGCedric Ghevaert
Cedric Ghevaert
Genome editing technologies such as zinc finger nucleases, TALENs and CRISPR/Cas9 have recently emerged as tools with the potential to revolutionise cellular therapy. This is particularly exciting for the field of regenerative medicine, where the large-scale, quality-controlled editing of large numbers of cells could generate essential cellular products ready to move towards the clinic. This review details recent progress towards generating HLA Class I null platelets using genome editing technologies for β2-microglobulin deletion, generating a universally transfusable cellular product. In addition, we discuss various methods for megakaryocyte (MK) production from human pluripotent stem cells and subsequent platelet production from the MKs. As well as simply producing platelets, differentiating MK cultures can enable us to understand megakaryopoiesis in vivo and take steps towards ameliorating bleeding disorders or deficiencies in MK maturation in patients. Thus by intersecting both these areas of research, we can produce optimised differentiation systems for the production of universal platelets, thus offering a stable supply of platelets for difficult-to-match patients and providing areas with transmissible disease concerns or an unpredictable supply of platelets with a steady supply of quality-controlled platelet units.